ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.665,19
-0,32%
S&P 500
5.297,10
-0,21%
Dow Jones
39.869,38
-0,10%
Euro vs US Dollar
1,08435
-0,22%
Bitcoin
66.349,00
1,70%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Kanada
  5. TSXV
  6. Quest PharmaTech Inc (QPT)

  7. Quest PharmaTech Inc (QPT) News

QPT

Quest PharmaTech (QPT)

Quest PharmaTech Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:TSXV:QPT
DatumZeitQuelleÜberschriftSymbolFirma
30/01/202423h00PR Newswire (Canada)Quest Receives Cash Dividend Payment from OncoQuestTSXV:QPTQuest PharmaTech Inc
23/01/202423h49PR Newswire (Canada)Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical BenefitsTSXV:QPTQuest PharmaTech Inc
13/09/202322h15PR Newswire (Canada)Quest PharmaTech Provides Corporate UpdateTSXV:QPTQuest PharmaTech Inc
14/07/202322h30PR Newswire (Canada)Quest PharmaTech Announces Results from AGMTSXV:QPTQuest PharmaTech Inc
10/07/202322h30PR Newswire (Canada)Quest PharmaTech Provides Product Development UpdateTSXV:QPTQuest PharmaTech Inc
09/06/202323h00PR Newswire (Canada)Quest PharmaTech Provides Corporate UpdateTSXV:QPTQuest PharmaTech Inc
07/06/202313h52PR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - QPTTSXV:QPTQuest PharmaTech Inc
07/06/202313h50PR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - QPTTSXV:QPTQuest PharmaTech Inc
06/06/202323h15PR Newswire (Canada)Quest PharmaTech Clarifies Agreement in Principle with OQP Bio Inc.TSXV:QPTQuest PharmaTech Inc
06/06/202314h03PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - QPTTSXV:QPTQuest PharmaTech Inc
06/06/202314h00PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - QPTTSXV:QPTQuest PharmaTech Inc
02/06/202323h05PR Newswire (Canada)Quest PharmaTech Provides Corporate UpdateTSXV:QPTQuest PharmaTech Inc
28/09/202223h00PR Newswire (Canada)Quest PharmaTech Announces Sale of Bioceltran Investment and Return of Photodynamic Therapy Technology LicenseTSXV:QPTQuest PharmaTech Inc
21/07/202223h00PR Newswire (Canada)Quest PharmaTech Announces Results from AGMTSXV:QPTQuest PharmaTech Inc
19/04/202213h00PR Newswire (Canada)Quest PharmaTech Provides Corporate UpdateTSXV:QPTQuest PharmaTech Inc
01/09/202123h15PR Newswire (Canada)OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian CancerTSXV:QPTQuest PharmaTech Inc
07/07/202123h15PR Newswire (Canada)Quest PharmaTech Announces Results from AGMTSXV:QPTQuest PharmaTech Inc
01/06/202121h00PR Newswire (Canada)Quest PharmaTech announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American As...TSXV:QPTQuest PharmaTech Inc
27/03/202100h14PR Newswire (Canada)Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.TSXV:QPTQuest PharmaTech Inc
02/02/202123h00PR Newswire (Canada)Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.TSXV:QPTQuest PharmaTech Inc
05/01/202123h15PR Newswire (Canada)Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.TSXV:QPTQuest PharmaTech Inc
09/11/202023h30PR Newswire (Canada)Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead...TSXV:QPTQuest PharmaTech Inc
04/06/202023h05PR Newswire (Canada)Quest Provides Corporate UpdateTSXV:QPTQuest PharmaTech Inc
02/06/202022h11PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - QPTTSXV:QPTQuest PharmaTech Inc
02/06/202022h08PR Newswire (Canada)IIROC Trading Resumption - QPTTSXV:QPTQuest PharmaTech Inc
04/05/202017h16PR Newswire (Canada)MISE À JOUR - Suspension de la négociation par l'OCRCVM - QPTTSXV:QPTQuest PharmaTech Inc
04/05/202017h10PR Newswire (Canada)UPDATE - IIROC Trading Halt - QPTTSXV:QPTQuest PharmaTech Inc
01/05/202022h30PR Newswire (Canada)Quest PharmaTech Announces Results from its April 28, 2020 AGMTSXV:QPTQuest PharmaTech Inc
22/04/202019h10PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - QPTTSXV:QPTQuest PharmaTech Inc
22/04/202019h07PR Newswire (Canada)IIROC Trading Halt - QPTTSXV:QPTQuest PharmaTech Inc
 Showing the most relevant articles for your search:TSXV:QPT

Kürzlich von Ihnen besucht

EU
G021T
G021T
NASDAQ
SYSN
Synetics
LSE
MNKS
Monks Investment
NASDAQ
SHCR
Sharecare
EU
D279T
D279T
USOTC
GUARL
Guaranty Trust Bank ()
TSX
NSSB
NBI Sustainable Canadian...
COIN
ICNQUSD
Iconiq Lab Token
USOTC
GTHKF
Genting Hong Kong (CE)
NASDAQ
ADTDX
Allspring Dynamic Target...
COIN
ERCOGBP
Belance ERC20 [OLD]
COIN
DADBTC
DAD
NASDAQ
HSCS
Heart Test Laboratories
NASDAQ
ABAQBXX
Jpmorgan Chase Bank Na P...
BIT
I06282
Banca Imi
AMEX
PXH
Invesco FTSE RAFI Emergi...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten